Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolfo Sacco

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
Journal of Personalized Medicine|October 23, 2021
TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular CarcinomaAlessandro Granito, Antonio Facciorusso, Rodolfo Sacco, et al.
BMC Cancer|July 7, 2018
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysisCarla Rognoni, Oriana Ciani, Silvia Sommariva, et al.
Cancers|June 24, 2022
Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic ReviewDaryl Ramai, Smit S Deliwala, Saurabh Chandan, et al.
The International Journal of Biological Markers|June 8, 2018
Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patientsBrian I Carr, Gianluigi Giannelli, Vito Guerra, et al.
Expert Review of Anticancer Therapy|August 1, 2012
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?Rodolfo Sacco, Irene Bargellini, Barbara Ginanni, et al.
Cancers|February 25, 2023
Reply to Lissing et al. Comment on "Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. <i>Cancers</i> 2022, <i>14</i>, 2947"Daryl Ramai, Smit S Deliwala, Saurabh Chandan, et al.
Advanced Healthcare Materials|June 4, 2015
Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid NanoparticlesAgostina Grillone, Eugenio Redolfi Riva, Alessio Mondini, et al.
Clinical and Translational Gastroenterology|January 14, 2021
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With SorafenibVito Sansone, Francesco Tovoli, Andrea Casadei-Gardini, et al.
Future Oncology (London, England)|August 10, 2018
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life studyRodolfo Sacco, Alessandro Granito, Irene Bargellini, et al.
Hepatology (Baltimore, Md.)|November 23, 2017
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort studyMauro Borzio, Elena Dionigi, Angelo Rossini, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
Journal of Personalized Medicine|October 23, 2021
TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular CarcinomaAlessandro Granito, Antonio Facciorusso, Rodolfo Sacco, et al.
BMC Cancer|July 7, 2018
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysisCarla Rognoni, Oriana Ciani, Silvia Sommariva, et al.
Cancers|June 24, 2022
Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic ReviewDaryl Ramai, Smit S Deliwala, Saurabh Chandan, et al.
The International Journal of Biological Markers|June 8, 2018
Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patientsBrian I Carr, Gianluigi Giannelli, Vito Guerra, et al.
Expert Review of Anticancer Therapy|August 1, 2012
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?Rodolfo Sacco, Irene Bargellini, Barbara Ginanni, et al.
Cancers|February 25, 2023
Reply to Lissing et al. Comment on "Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. <i>Cancers</i> 2022, <i>14</i>, 2947"Daryl Ramai, Smit S Deliwala, Saurabh Chandan, et al.
Advanced Healthcare Materials|June 4, 2015
Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid NanoparticlesAgostina Grillone, Eugenio Redolfi Riva, Alessio Mondini, et al.
Clinical and Translational Gastroenterology|January 14, 2021
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With SorafenibVito Sansone, Francesco Tovoli, Andrea Casadei-Gardini, et al.
Future Oncology (London, England)|August 10, 2018
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life studyRodolfo Sacco, Alessandro Granito, Irene Bargellini, et al.
Hepatology (Baltimore, Md.)|November 23, 2017
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort studyMauro Borzio, Elena Dionigi, Angelo Rossini, et al.
Pageof 17